Re: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
Bria
Emilio
E
Carlini
Paolo
P
Cognetti
Francesco
F
Terzoli
Edmondo
E
Giannarelli
Diana
D
D000730:Androstadienes / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D015201:Meta-Analysis as Topic; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000401:mortality; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012107:Research Design; D016019:Survival Analysis
D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; C056516:exemestane